Cargando…

Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome

High plasma matrix metalloproteases-9 (MMP-9) levels have been reported in Fragile X Syndrome in a limited number of animal and human studies. Since the results obtained are method-dependent and not directly comparable, the clinical utility of MMP-9 measurement in FXS remains unclear. This study aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Laroui, Asma, Galarneau, Luc, Abolghasemi, Armita, Benachenhou, Sérine, Plantefève, Rosalie, Bouchouirab, Fatima Zahra, Lepage, Jean François, Corbin, François, Çaku, Artuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470743/
https://www.ncbi.nlm.nih.gov/pubmed/36100610
http://dx.doi.org/10.1038/s41598-022-19476-y
_version_ 1784788911073001472
author Laroui, Asma
Galarneau, Luc
Abolghasemi, Armita
Benachenhou, Sérine
Plantefève, Rosalie
Bouchouirab, Fatima Zahra
Lepage, Jean François
Corbin, François
Çaku, Artuela
author_facet Laroui, Asma
Galarneau, Luc
Abolghasemi, Armita
Benachenhou, Sérine
Plantefève, Rosalie
Bouchouirab, Fatima Zahra
Lepage, Jean François
Corbin, François
Çaku, Artuela
author_sort Laroui, Asma
collection PubMed
description High plasma matrix metalloproteases-9 (MMP-9) levels have been reported in Fragile X Syndrome in a limited number of animal and human studies. Since the results obtained are method-dependent and not directly comparable, the clinical utility of MMP-9 measurement in FXS remains unclear. This study aimed to compare quantitative gel zymography and ELISA and to determine which method better discriminates abnormal MMP-9 levels of individuals with FXS from healthy controls and correlates with the clinical profile. The active and total forms of MMP-9 were quantified respectively, by gel zymography and ELISA in a cohort of FXS (n = 23) and healthy controls (n = 20). The clinical profile was assessed for the FXS group using the Aberrant Behavior Checklist FXS adapted version (ABC-C(FX)), Adaptive Behavior Assessment System (ABAS), Social Communication Questionnaire (SCQ), and Anxiety Depression and Mood Scale questionnaires. Method comparison showed a disagreement between gel zymography and ELISA with a constant error of − 0.18 [95% CI: − 0.35 to − 0.02] and a proportional error of 2.31 [95% CI: 1.53 to 3.24]. Plasma level of MMP-9 active form was significantly higher in FXS (n = 12) as compared to their age-sex and BMI matched controls (n = 12) (p = 0.039) and correlated with ABC-C(FX) (r(s) = 0.60; p = 0.039) and ADAMS (r(s) = 0.57; p = 0.043) scores. As compared to the plasma total form, the plasma MMP-9 active form better enables the discrimination of individuals with FXS from controls and correlates with the clinical profile. Our results highlight the importance of choosing the appropriate method to quantify plasma MMP-9 in future FXS clinical studies.
format Online
Article
Text
id pubmed-9470743
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-94707432022-09-15 Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome Laroui, Asma Galarneau, Luc Abolghasemi, Armita Benachenhou, Sérine Plantefève, Rosalie Bouchouirab, Fatima Zahra Lepage, Jean François Corbin, François Çaku, Artuela Sci Rep Article High plasma matrix metalloproteases-9 (MMP-9) levels have been reported in Fragile X Syndrome in a limited number of animal and human studies. Since the results obtained are method-dependent and not directly comparable, the clinical utility of MMP-9 measurement in FXS remains unclear. This study aimed to compare quantitative gel zymography and ELISA and to determine which method better discriminates abnormal MMP-9 levels of individuals with FXS from healthy controls and correlates with the clinical profile. The active and total forms of MMP-9 were quantified respectively, by gel zymography and ELISA in a cohort of FXS (n = 23) and healthy controls (n = 20). The clinical profile was assessed for the FXS group using the Aberrant Behavior Checklist FXS adapted version (ABC-C(FX)), Adaptive Behavior Assessment System (ABAS), Social Communication Questionnaire (SCQ), and Anxiety Depression and Mood Scale questionnaires. Method comparison showed a disagreement between gel zymography and ELISA with a constant error of − 0.18 [95% CI: − 0.35 to − 0.02] and a proportional error of 2.31 [95% CI: 1.53 to 3.24]. Plasma level of MMP-9 active form was significantly higher in FXS (n = 12) as compared to their age-sex and BMI matched controls (n = 12) (p = 0.039) and correlated with ABC-C(FX) (r(s) = 0.60; p = 0.039) and ADAMS (r(s) = 0.57; p = 0.043) scores. As compared to the plasma total form, the plasma MMP-9 active form better enables the discrimination of individuals with FXS from controls and correlates with the clinical profile. Our results highlight the importance of choosing the appropriate method to quantify plasma MMP-9 in future FXS clinical studies. Nature Publishing Group UK 2022-09-13 /pmc/articles/PMC9470743/ /pubmed/36100610 http://dx.doi.org/10.1038/s41598-022-19476-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Laroui, Asma
Galarneau, Luc
Abolghasemi, Armita
Benachenhou, Sérine
Plantefève, Rosalie
Bouchouirab, Fatima Zahra
Lepage, Jean François
Corbin, François
Çaku, Artuela
Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome
title Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome
title_full Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome
title_fullStr Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome
title_full_unstemmed Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome
title_short Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome
title_sort clinical significance of matrix metalloproteinase-9 in fragile x syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470743/
https://www.ncbi.nlm.nih.gov/pubmed/36100610
http://dx.doi.org/10.1038/s41598-022-19476-y
work_keys_str_mv AT larouiasma clinicalsignificanceofmatrixmetalloproteinase9infragilexsyndrome
AT galarneauluc clinicalsignificanceofmatrixmetalloproteinase9infragilexsyndrome
AT abolghasemiarmita clinicalsignificanceofmatrixmetalloproteinase9infragilexsyndrome
AT benachenhouserine clinicalsignificanceofmatrixmetalloproteinase9infragilexsyndrome
AT plantefeverosalie clinicalsignificanceofmatrixmetalloproteinase9infragilexsyndrome
AT bouchouirabfatimazahra clinicalsignificanceofmatrixmetalloproteinase9infragilexsyndrome
AT lepagejeanfrancois clinicalsignificanceofmatrixmetalloproteinase9infragilexsyndrome
AT corbinfrancois clinicalsignificanceofmatrixmetalloproteinase9infragilexsyndrome
AT cakuartuela clinicalsignificanceofmatrixmetalloproteinase9infragilexsyndrome